14:34 EST Edgewise moves off lows after stating FDA warning unrelated to company
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise should be bought on weakness as ARCH not likely FDA focus, says Truist
- Edgewise falls after FDA posts Warning Letter to trial investigator
- Edgewise Therapeutics price target raised to $50 from $33 at Truist
- Edgewise Therapeutics initiated with an Outperform at Evercore ISI
- Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials